Home › Funds › T. Rowe Price Associates › ABBV

T. Rowe Price Associates position in ABBV

ABBVIE INC · Health Care

T. Rowe Price Associates reported holding 14,759,347 shares of ABBV (ABBVIE INC) in its Q3 2026 13F filing — a position valued at US$3.86B, representing 0.39% of its reported portfolio and ranking #42 among its reported holdings. T. Rowe Price Associates has disclosed ABBV holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

Latest position (Q3 2026)14.76M sh
Reported value held$3.86B
Portfolio Weight0.39%
First reportedQ3 2021
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How T. Rowe Price Associates's ABBV position evolved

T. Rowe Price Associates first disclosed a stake in ABBV in Q3 2021 at 26,208,021 shares (US$2.83B). The position peaked in Q1 2022 at 36,732,127 shares, worth US$5.95B. Across 21 filings, T. Rowe Price Associates increased the stake 8 time(s), trimmed it 11 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 14,759,347 shares valued at US$3.86B. Notable position changes include a 26% trim in Q4 2023 (shares rose 19% over the following quarter), a 29% trim in Q1 2025 (shares fell 11% over the following quarter), a 32% increase in Q1 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2021 26.21M $2.83B New
Q4 2021 32.59M $4.41B Add
Q1 2022 36.73M $5.95B Add
Q2 2022 30.81M $4.72B Reduce
Q3 2022 24.52M $3.29B Reduce
Q4 2022 20.42M $3.30M Reduce
Q1 2023 17.58M $2.80M Reduce
Q2 2023 13.16M $1.77M Reduce
Q3 2023 12.81M $1.91M Reduce
Q4 2023 9.45M $1.46M Reduce
Q1 2024 10.74M $1.96M Add
Q2 2024 10.94M $1.88M Add
Q3 2024 10.26M $2.03M Reduce
Q4 2024 10.19M $1.81M Reduce
Q1 2025 7.19M $1.51M Reduce
Q2 2025 9.06M $1.68M Add
Q3 2025 10.60M $2.45M Add
Q4 2025 9.83M $2.25M Reduce
Q1 2026 13.00M $2.83M Add
Q2 2026 14.75M $3.71M Add
Q3 2026 14.76M $3.86B Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABBV and 13F data

ABBV (ABBVIE INC) is a Health Care company. 33 other funds we track also report a position in ABBV — the largest reported positions include Vanguard Group (US$41.31B), BlackRock Inc (US$38.97B), VANGUARD CAPITAL MANAGEMENT LLC (US$30.26B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABBV

All ABBV fund holders →

FAQ

How long has T. Rowe Price Associates held ABBV?

T. Rowe Price Associates has disclosed ABBV holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

What is T. Rowe Price Associates's current position in ABBV?

As of Q3 2026, T. Rowe Price Associates holds 14.76M shares of ABBV (ABBVIE INC), valued at $3.86B, representing 0.39% of its reported portfolio and ranking #42.

Has T. Rowe Price Associates been buying or selling ABBV?

In the latest 13F filing (Q3 2026), T. Rowe Price Associates held unchanged its position in ABBV. The position peaked in Q1 2022 at 36.73M shares.

Which other funds hold ABBV?

Other major institutional holders of ABBV include Vanguard Group, BlackRock Inc, VANGUARD CAPITAL MANAGEMENT LLC, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.